Media headlines about TearLab Corporation (NASDAQ:TEAR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TearLab Corporation earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.8254958620871 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

TEAR has been the subject of several recent analyst reports. Zacks Investment Research upgraded TearLab Corporation from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Thursday, May 11th. Rodman & Renshaw dropped their price objective on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of TearLab Corporation in a research note on Tuesday, May 16th. Five investment analysts have rated the stock with a buy rating, TearLab Corporation has an average rating of “Buy” and a consensus price target of $4.95.

TearLab Corporation (NASDAQ TEAR) traded up 2.31% on Friday, reaching $1.33. The company’s stock had a trading volume of 206,248 shares. The company has a 50-day moving average price of $2.03 and a 200 day moving average price of $2.64. The company’s market cap is $7.64 million. TearLab Corporation has a 12 month low of $1.20 and a 12 month high of $8.20.

TearLab Corporation (NASDAQ:TEAR) last posted its quarterly earnings data on Monday, August 14th. The medical research company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. The company had revenue of $7 million during the quarter, compared to analysts’ expectations of $6.86 million. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) earnings per share. On average, equities research analysts anticipate that TearLab Corporation will post ($2.70) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect TearLab Corporation (TEAR) Stock Price” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Insider Buying and Selling by Quarter for TearLab Corporation (NASDAQ:TEAR)

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.